In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

British Biotech licenses ImmunoGen's cancer drug;terminated

Executive Summary

Broadening its cancer platform, British Biotech has licensed exclusive Japanese and European Union rights to ImmunoGen's tumor-activated prodrug, huN901-DM1, for small-cell lung cancer, paying an up-front fee of (uf)$1.5mm, plus royalties on sales in these territories.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register